Search

Displaying results 4191 - 4200 of 8010 in total
  1. Drug

    ATHX-105

    go.drugbank.com/drugs/DB06008
    Investigational

    ATHX-105 is an investigational selective 5HT2c receptor agonist developed by Athersys Inc. for the treatment of Obesity.

  2. Drug

    Phencyclidine

    go.drugbank.com/drugs/DB03575
    ExperimentalIllicit

    A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to ketamine in structure and in many of its effects.

  3. Drug

    Streptococcus pneumoniae type 6a capsular polysaccharide antigen

    go.drugbank.com/drugs/DB16609
    ApprovedInvestigational

    Mixtures: Prevenar 13 Suspension For Injection, SII PNEUMOSIL Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) (10-Valent) SUSPENSION FOR INJECTION (SINGLE DOSE - 1 DOSE)
  4. Drug

    Nafarelin

    go.drugbank.com/drugs/DB00666
    ApprovedInvestigational

    Nafarelin is a potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central precocious puberty and endometriosis.

  5. Drug

    NP-6A4

    go.drugbank.com/drugs/DB17599
    Experimental

    It has an Orphan Drug designation from the FDA for pediatric cardiomyopathy.[A258523]

  6. Drug

    Smallpox (Vaccinia) Vaccine, Live

    go.drugbank.com/drugs/DB14711
    ApprovedInvestigational

    [L12747] In August 2024, ACAM2000 was additionally approved for the prevention of mpox infection in high-risk individuals.[L51499] … [L12747] ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain.

  7. Drug

    Acadesine

    go.drugbank.com/drugs/DB04944
    Investigational

    It is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU. … Acadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing

  8. Drug

    Leriglitazone

    go.drugbank.com/drugs/DB15021
    Investigational

    Leriglitazone is under investigation in clinical trial NCT03917225 (A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients).

  9. Drug

    Affitope AD01

    go.drugbank.com/drugs/DB06086
    Investigational

    Affitope AD01 is an investigational drug developed for immunization to treat Alzheimer's Disease.

  10. Drug

    RESP301

    go.drugbank.com/drugs/DB16497
    Investigational

    RESP301 was under investigation in clinical trials for various conditions. … Additionally, RESP301 was investigated in a withdrawn trial (NCT04842331) for preventing viral exposure and transmission of COVID-19 and in a not yet recruiting trial (NCT04386070) for preventing pulmonary

    Categories: Experimental Unapproved Treatments for COVID-19